Cannabinoid Modulation of Noradrenergic Circuits: Implications for Psychiatric Disorders

Overview

Journal Prog Neuropsychopharmacol Biol Psychiatry

Specialty Psychiatry

Date 2012 Feb 3

PMID 22296986

Citations 18

Authors

Ana Franky Carvalho

Elisabeth J Van Bockstaele

Affiliations

Soon will be listed here.

Abstract

The interaction between the endocannabinoid system and catecholaminergic circuits has gained increasing attention as it is recognized that the development of synthetic cannabinoid receptor agonists/antagonists or compounds targeting endocannabinoid synthesis/metabolism may hold some therapeutic potential for the treatment of psychiatric disorders. The noradrenergic system plays a critical role in the modulation of emotional state, primarily related to anxiety, arousal, and stress. Recent evidence suggests that the endocannabinoid system mediates stress responses and emotional homeostasis, in part, by targeting noradrenergic circuits. This review summarizes our current knowledge regarding the anatomical substrates underlying regulation of noradrenergic circuitry by the endocannabinoid system. It then presents biochemical evidence showing an important effect of cannabinoid modulation on adrenergic receptor signaling. Finally, new evidence from behavioral pharmacology studies is provided demonstrating that norepinephrine is a critical determinant of cannabinoid-induced aversion, adding another dimension to how central noradrenergic circuitry is regulated by the cannabinoid system.

Citing Articles

UK Medical Cannabis Registry: An analysis of clinical outcomes of medicinal cannabis therapy for attention-deficit/hyperactivity disorder.

Ittiphakorn P, Erridge S, Holvey C, Coomber R, Rucker J, Sodergren M Neuropsychopharmacol Rep. 2023; 43(4):596-606.

PMID: 38058251 PMC: 10739081. DOI: 10.1002/npr2.12400.

Targeting the cannabinoid system to counteract the deleterious effects of stress in Alzheimer's disease.

Shade R, Ross J, Van Bockstaele E Front Aging Neurosci. 2022; 14:949361.

PMID: 36268196 PMC: 9577232. DOI: 10.3389/fnagi.2022.949361.

The endocannabinoid system in social anxiety disorder: from pathophysiology to novel therapeutics.

Ahmed M, Boileau I, Le Foll B, Carvalho A, Kloiber S Braz J Psychiatry. 2021; 44(1):81-93.

PMID: 34468550 PMC: 8827369. DOI: 10.1590/1516-4446-2021-1926.

The neuropharmacology of cannabinoid receptor ligands in central signaling pathways.

Brunt T, Bossong M Eur J Neurosci. 2020; 55(4):909-921.

PMID: 32974975 PMC: 9291836. DOI: 10.1111/ejn.14982.

A Guide to Targeting the Endocannabinoid System in Drug Design.

Stasiulewicz A, Znajdek K, Grudzien M, Pawinski T, Sulkowska A Int J Mol Sci. 2020; 21(8).

PMID: 32316328 PMC: 7216112. DOI: 10.3390/ijms21082778.

References

Walker D, Toufexis D, Davis M . Role of the bed nucleus of the stria terminalis versus the amygdala in fear, stress, and anxiety. Eur J Pharmacol. 2003; 463(1-3):199-216. DOI: 10.1016/s0014-2999(03)01282-2. View

Carvalho A, Van Bockstaele E . Direct intra-accumbal infusion of a beta-adrenergic receptor antagonist abolishes WIN 55,212-2-induced aversion. Neurosci Lett. 2011; 500(1):82-5. PMC: 3232734. DOI: 10.1016/j.neulet.2011.06.008. View

Jelsing J, Larsen P, Vrang N . Identification of cannabinoid type 1 receptor expressing cocaine amphetamine-regulated transcript neurons in the rat hypothalamus and brainstem using in situ hybridization and immunohistochemistry. Neuroscience. 2008; 154(2):641-52. DOI: 10.1016/j.neuroscience.2008.03.051. View

Swank M . Conditioned c-Fos in mouse NTS during expression of a learned taste aversion depends on contextual cues. Brain Res. 2000; 862(1-2):138-44. DOI: 10.1016/s0006-8993(00)02101-6. View

Strakowski S, DelBello M, Fleck D, Adler C, Anthenelli R, Keck Jr P . Effects of co-occurring cannabis use disorders on the course of bipolar disorder after a first hospitalization for mania. Arch Gen Psychiatry. 2007; 64(1):57-64. DOI: 10.1001/archpsyc.64.1.57. View

Patten S . Propranolol and depression: evidence from the antihypertensive trials. Can J Psychiatry. 1990; 35(3):257-9. DOI: 10.1177/070674379003500312. View

Wong M, Kling M, Munson P, Listwak S, Licinio J, Prolo P . Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features: relation to hypercortisolism and corticotropin-releasing hormone. Proc Natl Acad Sci U S A. 2000; 97(1):325-30. PMC: 26662. DOI: 10.1073/pnas.97.1.325. View

Zuardi A . History of cannabis as a medicine: a review. Braz J Psychiatry. 2006; 28(2):153-7. DOI: 10.1590/s1516-44462006000200015. View

Tzavara E, Davis R, Perry K, Li X, Salhoff C, Bymaster F . The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. Br J Pharmacol. 2003; 138(4):544-53. PMC: 1573706. DOI: 10.1038/sj.bjp.0705100. View

10.

Murray J, Bevins R . Cannabinoid conditioned reward and aversion: behavioral and neural processes. ACS Chem Neurosci. 2010; 1(4):265-278. PMC: 2873219. DOI: 10.1021/cn100005p. View

11.

Carr G, White N . Anatomical disassociation of amphetamine's rewarding and aversive effects: an intracranial microinjection study. Psychopharmacology (Berl). 1986; 89(3):340-6. DOI: 10.1007/BF00174372. View

12.

Delfs J, Zhu Y, Druhan J, Aston-Jones G . Noradrenaline in the ventral forebrain is critical for opiate withdrawal-induced aversion. Nature. 2000; 403(6768):430-4. DOI: 10.1038/35000212. View

13.

Zygmunt P, Petersson J, Andersson D, Chuang H, Sorgard M, Di Marzo V . Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature. 1999; 400(6743):452-7. DOI: 10.1038/22761. View

14.

Carvalho A, Mackie K, Van Bockstaele E . Cannabinoid modulation of limbic forebrain noradrenergic circuitry. Eur J Neurosci. 2010; 31(2):286-301. PMC: 3272673. DOI: 10.1111/j.1460-9568.2009.07054.x. View

15.

Carlezon Jr W . Place conditioning to study drug reward and aversion. Methods Mol Med. 2003; 84:243-9. DOI: 10.1385/1-59259-379-8:243. View

16.

Gottschalk L, Stone W, GLESER G . Peripheral versus central mechanisms accounting for antianxiety effects of propranolol. Psychosom Med. 1974; 36(1):47-56. DOI: 10.1097/00006842-197401000-00004. View

17.

Johns A . Psychiatric effects of cannabis. Br J Psychiatry. 2001; 178:116-22. DOI: 10.1192/bjp.178.2.116. View

18.

Velez C, Johnson J, Cohen P . A longitudinal analysis of selected risk factors for childhood psychopathology. J Am Acad Child Adolesc Psychiatry. 1989; 28(6):861-4. DOI: 10.1097/00004583-198911000-00009. View

19.

Sara S . The locus coeruleus and noradrenergic modulation of cognition. Nat Rev Neurosci. 2009; 10(3):211-23. DOI: 10.1038/nrn2573. View

20.

Bond D, Noronha M, Kauer-SantAnna M, Lam R, Yatham L . Antidepressant-associated mood elevations in bipolar II disorder compared with bipolar I disorder and major depressive disorder: a systematic review and meta-analysis. J Clin Psychiatry. 2009; 69(10):1589-601. DOI: 10.4088/jcp.v69n1009. View